Loading organization details...
Loading organization details...
Source: IRS Form 990 via ProPublica Nonprofit Explorerⓘ Leadership data below reflects a more recent filing (Tax Year 2024) from the IRS e-file system.
Total Revenue
▼$656.3M
Total Contributions
$226.1M
Total Expenses
▼$647.8M
Total Assets
$2.1B
Total Liabilities
▼$1.1B
Net Assets
$927.4M
Officer Compensation
→$3.9M
Other Salaries
$354M
Investment Income
▼$55.1M
Fundraising
▼$0
Source: USAspending.gov · Searched by organization name
VA/DoD Awards
$2.8M
VA/DoD Award Count
13
Funding from the Department of Veterans Affairs and/or Department of Defense.
Total Federal Funding
$38.3M
Awards Found
41
| Awarding Agency | Description | Amount | Fiscal Year | Period |
|---|---|---|---|---|
| Department of Health and Human Services | VANCOUVER DRUG USERS STUDY: EVALUATING THE NATURAL HISTORY OF INJECTION DRUG USE | $12.1M | FY2015 | Mar 2015 – Apr 2026 |
| Department of Health and Human Services | LOCALIZED ECONOMIC MODELING TO OPTIMIZE PUBLIC HEALTH STRATEGIES FOR HIV TREATMENT AND PREVENTION | $5.4M | FY2016 | Mar 2016 – Aug 2026 |
| Department of Health and Human Services | SYNTHETIC BACTERIAL ANALOGS OF MAMMALIAN OLIGOMANNOSE FOR ELICITING NEUTRALIZING ANTIBODIES TO THE HIGH-MANNOSE PATCH ON HIV ENV | $3.8M | FY2017 | Sep 2017 – Jul 2027 |
| Department of Health and Human Services | TOBACCO COMPANIES, PUBLIC POLICY AND GLOBAL HEALTH | $2.7M | FY2001 | Sep 2001 – Dec 2018 |
| Department of Health and Human Services | VACCINES THAT REPLICATE THE NEUTRALIZATION-COMPETENT STRUCTURE OF THE GP41 MPER | $2.7M | FY2012 | Mar 2012 – Feb 2018 |
| Department of Health and Human Services | DAT-EMULATING TARGET TRIALS WITH BIG DATA TO STRENGTHEN THE EVIDENCE BASE FOR THE CLINICAL MANAGEMENT OF OPIOID USE DISORDER - ABSTRACT DAT18-06 IN 2016, FOLLOWING A DRAMATIC INCREASE IN OPIOID-RELATED OVERDOSE DEATHS, THE PROVINCE OF BRITISH COLUMBIA (BC), CANADA DECLARED A PUBLIC HEALTH EMERGENCY. BC REPORTED 1,510 ILLICIT DRUG OVERDOSE DEATHS IN 2018, A RATE OF 31.0 PER 100,000, PLACING IT 10TH AMONG US STATES, EQUAL TO RHODE ISLAND (31.0), BEHIND WEST VIRGINIA (57.8), OHIO (46.3) AND PENNSYLVANIA (44.3) BUT AHEAD OF NEW JERSEY (30.0), MICHIGAN (27.8) AND FLORIDA (25.1). WHILE THE FOUR-FOLD INCREASE IN OVERDOSE DEATHS OBSERVED SINCE 2012 IS LARGELY ATTRIBUTABLE TO THE CONTAMINATION OF FENTANYL AND OTHER SYNTHETIC OPIOIDS IN THE ILLICIT DRUG SUPPLY, MANY DECEDENTS HAD SOUGHT TREATMENT IN THE PAST AND EXPERIENCED RELAPSES. OPIOID AGONIST TREATMENT (OAT) IS AMONG THE MOST EFFECTIVE TOOLS AVAILABLE TO COMBAT THE EPIDEMIC. HOWEVER, OAT UPTAKE AND RETENTION IS SUB-OPTIMAL IN BC AND INTERNATIONALLY, COMPROMISED LARGELY BY SOCIAL AND STRUCTURAL FACTORS BUT ALSO DEVIATIONS FROM EVIDENCE-BASED STANDARDS OF CARE AND FRAGMENTED CARE, PARTICULARLY FOR THOSE WITH CONCURRENT DISORDERS. FURTHERMORE, A NUMBER OF ASPECTS OF CANADIAN AND US CLINICAL GUIDELINES FOR THE MANAGEMENT OF OPIOID USE DISORDER (OUD) ARE BASED ON LIMITED AND LOW-QUALITY EVIDENCE. EVEN BASIC EVIDENCE ON THE COMPARATIVE EFFECTIVENESS OF AVAILABLE TREATMENT OPTIONS OVERALL AND FOR KEY POPULATIONS IN THE FENTANYL ERA IS LACKING. THIS PROPOSAL AIMS TO APPLY CUTTING-EDGE METHODS FOR CAUSAL INFERENCE IN EMULATING A SERIES OF ‘TARGET TRIALS’ IN THREE IMMEDIATE AIMS: (1) TO DETERMINE THE COMPARATIVE EFFECTIVENESS OF METHADONE VERSUS BUPRENORPHINE/NALOXONE FOR DIFFERENT PATIENT SUBGROUPS PRESENTING FOR OAT; (2) TO DETERMINE THE IMPACT OF URINE DRUG SCREENING – A UBIQUITOUS AND NON-EVIDENCE- BASED ELEMENT OF OUD CARE – ON OAT RETENTION AND MORTALITY; AND (3) TO DETERMINE THE COMPLEMENTARY EFFECTS OF OAT ON UPTAKE AND ADHERENCE TO DIRECTING-ACTING ANTIVIRALS FOR PEOPLE WITH OPIOID USE DISORDER (PWOUD) WITH CONCURRENT HEPATITIS C VIRUS. THE ‘TARGET TRIAL’ FRAMEWORK CHANNELS COUNTERFACTUAL THEORY IN PROVIDING A FLEXIBLE BASIS FOR COMPARING THE EFFECTS OF TREATMENT AND CLINICAL MANAGEMENT STRATEGIES ON EITHER AN INTENT-TO-TREAT OR PER-PROTOCOL BASIS. WE HAVE IDENTIFIED A NUMBER OF ADDITIONAL QUESTIONS RELATED TO THE CLINICAL MANAGEMENT OF PWOUD WHERE GUIDELINES ARE SUPPORTED BY WEAKER EMPIRICAL EVIDENCE AND WILL ENDEAVOR TO ANSWER AS MANY OF THESE QUESTIONS AS POSSIBLE, PRIORITIZING ANALYSIS USING A COMMON FRAMEWORK FOCUSED ON METHODOLOGICAL RIGOR AND | $2.4M | FY2021 | Mar 2021 – Jan 2027 |
| Department of Health and Human Services | HAART OPTIMISM, DRUG USE AND RISKY SEXUAL BEHAVIOR AMONG MSM IN BRITISH COLUMBIA. | $2M | FY2011 | Apr 2011 – Mar 2017 |
| Department of Health and Human Services | AN ETHNO-EPIDEMIOLOGICAL STUDY TO ADVANCE HIV PREVENTION AND TREATMENT FOR PWUD | $1.7M | FY2017 | May 2017 – Apr 2024 |
| VA/DoDDepartment of Defense | DEVELOPMENT OF FERROELECTRIC MATERIALS WITH ENHANCED PIEZOELECTRIC AND OPTICAL PROPERTIES VIA DOMAIN ENGINEERING FOR ELECTROMECHANICAL TRANSDUCER APPL | $596.3K | FY2021 | Apr 2021 – Mar 2026 |
| VA/DoDDepartment of Defense | HIGH-PERFORMANCE PIEZO- AND FERROELECTRIC MATERIALS FOR ELECTROMECHANICAL TRANSDUCER APPLICATIONS | $594.2K | FY2013 | Jun 2013 – Sep 2018 |
| VA/DoDDepartment of Defense | DEVELOPMENT OF HIGH-PERFORMANCE PIEZO- AND FERROELECTRIC MATERIALS FOR ELECTROMECHANICAL TRANSDUCER APPLICATIONS | $448.5K | FY2016 | Sep 2016 – Dec 2021 |
| VA/DoDDepartment of Defense | CONTROL OF ENERGY MINIMIZATION IN HUMAN LOCOMOTION. | $331.1K | FY2013 | Aug 2013 – Jul 2016 |
| Department of Health and Human Services | FERTILITY DESIRE AND PREGNANCY IN A COHORT OF DISCORDANT UGANDAN COUPLES ON ART | $303K | FY2011 | Apr 2011 – Mar 2013 |
| Department of Health and Human Services | GENETICS, DYNAMICS AND FITNESS OF THE HIV-1 LATENT RESERVOIR | $300.2K | FY2018 | Jun 2018 – May 2021 |
| VA/DoDDepartment of Defense | DEVELOPMENT OF HIGH-PERFORMANCE PIEZO- AND FERRO-ELECTRIC MATERIALS FOR ELECTROMECHANICAL TRANSDUCTION APPLICATIONS | $299.7K | FY2010 | Jan 2010 – Dec 2011 |
| Department of Health and Human Services | EXPLORING ANTIBODY RECOGNITION OF THE V3 REGION ON HIV-1 TO GUIDE VACCINE DESIGN | $295.3K | FY2009 | Apr 2009 – Mar 2011 |
| Department of Health and Human Services | THE NON-FATAL OVERDOSE CRISIS: SEX AND GENDER DIFFERENCES IN HEALTHCARE UTILIZATION AND HEALTH OUTCOMES OF PEOPLE LIVING WITH AND WITHOUT HIV BETWEEN 2012 AND 2020 - PROJECT SUMMARY/ABSTRACT THE OVERDOSE (OD) CRISIS CONTINUES TO DEVASTATE COMMUNITIES ACROSS NORTH AMERICA. DESPITE 90% OF PARAMEDIC- ATTENDED ODS IN BRITISH COLUMBIA (BC), CANADA BEING NON-FATAL, MUCH OF THE RESEARCH HAS FOCUSED ON FATAL ODS. WHILE MEN ACCOUNT FOR OVER 70% OF FATAL ODS, THERE IS EVIDENCE OF A MORE BALANCED DISTRIBUTION OF MEN AND WOMEN EXPERIENCING NON-FATAL ODS (NFODS); FURTHER, WOMEN HAVE HIGHER MORTALITY RATES IN THE YEAR FOLLOWING AN NFOD. PEOPLE LIVING WITH HIV (PLHIV) ARE DISPROPORTIONATELY AFFECTED BY THE OD CRISIS AND ARE AT INCREASED RISK OF FATAL ODS, YET LITTLE IS KNOWN ABOUT THE LONGER-TERM IMPACTS OF NFODS ON PLHIV IN TERMS OF ADVERSE HEALTH OUTCOMES AND HEALTHCARE UTILIZATION (HCU). CONSIDERING THE INCREASINGLY HIGH RATES OF NFODS, GENDERED DIFFERENCES IN MORTALITY FOLLOWING AN NFOD, AND KNOWLEDGE GAPS CONCERNING HEALTH OUTCOMES FOLLOWING AN NFOD, THIS PROPOSAL SEEKS FUNDING TO INVESTIGATE THE ROLE OF SEX, GENDER, AND HIV STATUS IN DIFFERENTIAL NFOD OUTCOMES. BC’S UNIVERSAL HEALTHCARE SYSTEM AND DATA CENTRALIZATION ENABLED THE COMPARATIVE OUTCOMES AND SERVICE UTILIZATION TRENDS (COAST) STUDY, A POPULATION-BASED LONGITUDINAL COHORT COMPRISED OF LINKED ADMINISTRATIVE HEALTH DATASETS ON ALL KNOWN ADULT PLHIV AND A 10% RANDOM SAMPLE OF THE GENERAL POPULATION IN BC. USING COAST, WE AIM TO: (1) GENERATE ESTIMATES FOR THE INCIDENCE RATES OF FATAL AND NONFATAL ODS AMONG PEOPLE LIVING WITH AND WITHOUT HIV (2012-2020) IN BC; (2) ASSESS AND COMPARE CHANGES IN HEALTH CARE UTILIZATION, CHRONIC COMORBIDITY, AND MORTALITY AMONG PEOPLE LIVING WITH AND WITHOUT HIV WHO EXPERIENCED AN NFOD, MODIFIED BY SEX AND GENDER; AND (3) ASSESS AND COMPARE CHANGES IN HIV TREATMENT OUTCOMES IN PEOPLE LIVING WITH HIV WHO EXPERIENCED AN NFOD, MODIFIED BY SEX AND GENDER. THIS PROJECT WILL ALSO INVOLVE THE DEVELOPMENT OF A COMMUNITY ADVISORY BOARD (CAB) FOR PROPOSED AND FUTURE PROJECTS. THE CAB WILL PROVIDE GUIDANCE TO ENSURE RESEARCH SOUNDNESS AND RELEVANCE TO THE COMMUNITY THROUGHOUT THE RESEARCH AND KNOWLEDGE MOBILIZATION PROCESSES. OUR COLLABORATIVE RESEARCH WILL BE AN OPPORTUNITY TO EXPLORE OTHER RESEARCH POSSIBILITIES INITIATED BY THE CAB AS IMPORTANT FOR WOMEN AND GENDER MINORITIES LIVING WITH AND WITHOUT HIV WHO ARE AFFECTED BY THE OD CRISIS. IN RESPONSE TO THE NATIONAL INSTITUTE ON DRUG ABUSE NOTICE OF SPECIAL INTEREST NOT-DA- 21-021 TO ADVANCE RESEARCH SPECIFIC TO WOMEN AND OTHER UNDERREPRESENTED POPULATIONS INCLUDING GENDER MINORITIES, THIS PROPOSAL WILL INFORM FUTURE CAB-LED CYCLES OF INQUIRY AND ANALYSIS AMONGST OUR TEAM TO ANSWER RELEVANT RESEARCH QUESTIONS AND ADDRESS THE IDENTIFIED NEEDS OF CISGENDER WOMEN AND GENDER MINORITIES LIVING WITH AND WITHOUT HIV AFFECTED BY THE OD CRISIS. | $291.5K | FY2023 | Jul 2023 – Jun 2025 |
| Department of Health and Human Services | RELEVANCE OF SERUM MANNOSIDASE RESISTANCE TO THE SPECIFICITY OF OLIGOMANNOSE-TARGETING ANTIBODIES - PROJECT SUMMARY THE GLYCANS THAT DECORATE THE HIV ENVELOPE GLYCOPROTEIN SPIKE (ENV) ARE CATEGORIZED NOMINALLY AS ‘SELF’ ANTIGENS GIVEN THAT THEY ARE IMPARTED BY THE MAMMALIAN CELL’S GLYCOSYLATION MACHINERY. HOWEVER, GLYCANS OF THE OLIGOMANNOSE-TYPE FOUND ON GP120 ARE MOSTLY CLUSTERED INTO A PATCH, CREATING A ‘NON-SELF’ ARCHITECTURE. THIS OLIGOMANNOSE PATCH IS VULNERABLE TO RECOGNITION BY ANTI-HIV BROADLY NEUTRALIZING ANTIBODIES (BNABS). GIVEN THE POTENCY AND BREADTH OF BNABS TO THE OLIGOMANNOSE PATCH, THERE IS GREAT INTEREST IN DEVELOPING IMMUNIZATION STRATEGIES TO ELICIT SIMILAR BNABS. THIS PROJECT AIMS TO FILL A GAP IN UNDERSTANDING BARRIERS TO THE ELICITATION OF OLIGOMANNOSE-SPECIFIC BNABS. WE AND OTHERS HAVE RECENTLY REPORTED ON A SOLUBLE MANNOSIDASE FOUND IN MAMMALIAN SERUM THAT TRIMS OLIGOMANNOSIDES ON GLYCOCONJUGATES DESIGNED TO ELICIT OLIGOMANNOSE-SPECIFIC ANTIBODIES UPON IMMUNIZATION. SUCH TRIMMING WOULD EXPLAIN WHY IMMUNIZING WITH OLIGOMANNOSIDIC GLYCOCONJUGATES TYPICALLY YIELDS ANTIBODIES THAT BIND WELL TO SUBSTRUCTURES OF OLIGOMANNOSE BUT THAT BIND WITH SUBSTANTIALLY LOWER AVIDITY TO FULL-SIZED OLIGOMANNOSE AS PRESENTED ON ENV; THE LATTER TYPIFIES THE BINDING MANNER OF BNABS THAT TARGET THE OLIGOMANNOSE PATCH. IN THIS APPLICATION, WE PROPOSE TO DETERMINE THE EXTENT TO WHICH SERUM MANNOSIDASE ACTIVITY IS RELEVANT TO THE QUALITY OF OLIGOMANNOSE-SPECIFIC ANTIBODY RESPONSES. SPECIFICALLY, WE INTEND TO CONSTRUCT A MANNOSIDASE-RESISTANT GLYCOSIDE, THUS REPRESENTING THE GREATEST POSSIBLE RESISTANCE TO MANNOSIDASE TRIMMING, AND DETERMINE THE SPECIFICITY OF THE ENSUING ANTIBODY RESPONSE COMPARED TO ITS MANNOSIDASE- SENSITIVE OPPOSITE. THE PROJECT WILL TAKE ADVANTAGE OF OUR PUBLISHED WORK OF A BACTERIALLY INSPIRED MIMIC OF OLIGOMANNOSE THAT, AS A NEOGLYCOCONJUGATE, ELICITS MODEST LEVELS OF HIV-NEUTRALIZING ANTIBODIES. WE WILL INVESTIGATE ANTIBODY RESPONSES AT THE POLYCLONAL SERUM LEVEL AS WELL AS THE MONOCLONAL LEVEL; THE LATTER SHOULD REVEAL SIMILARITIES, IF ANY, BETWEEN THE ELICITED ANTIBODIES AND EXISTING BNABS. IN SUM, WE EXPECT THE RESULTS OF THIS PROJECT TO SHED LIGHT ON BARRIERS TO EVOKING ANTIBODIES WITH CAPACITY TO BIND THE HIGHLY VULNERABLE OLIGOMANNOSE PATCH ON HIV ENV. ALTHOUGH THE DIFFICULTY IN ELICITING OLIGOMANNOSE-SPECIFIC BNABS IS OFTEN ASSUMED TO STEM FROM B CELL TOLERANCE, OUR PRELIMINARY STUDIES PROVIDE EVIDENCE FOR SERUM MANNOSIDASE POSING AT LEAST AN ADDITIONAL HINDRANCE. | $288.3K | FY2021 | Jun 2021 – May 2024 |
| VA/DoDDepartment of Defense | DEVELOPMENT OF NOVEL HYBRID ORGANIC-INORGANIC HALIDE PEROVSKITE MATERIALS FOR PIEZOELECTRIC AND MULTIFUNCTIONAL DEVICES | $200K | FY2026 | Apr 2026 – Nov 2030 |
| Department of Health and Human Services | ORIGIN OF ANTIBODIES WITH LONG CDR-H3 LOOPS IN HIV INFECTION & AUTOIMMUNE DISEASE | $197.2K | FY2008 | Jun 2008 – May 2010 |
| Department of Agriculture | IDENTIFICATION CHARACTERIZATION AND VALIDATION OF GENETIC MUTATIONS INCURRED DURING IN VITRO ATTENUATION OF MAREK'S DISEASE VIRUS | $175.3K | FY2010 | Feb 2010 – Sep 2012 |
| VA/DoDDepartment of Defense | DEVELOPMENT OF HIGH-PERFORMANCE PIEZO- AND FERROELECTRIC SINGLE CRYSTALS FOR ELECTROMECHANICAL TRANSDUCER APPLICATIONS | $158.2K | FY2011 | Apr 2011 – Dec 2012 |
| VA/DoDDepartment of Defense | THE EFFECT OF NORMOXIC DIVES ON NARCOSIS AND HEART FUNCTION IN HUMAN AND CELLULAR MODELS | $126K | FY2014 | Jun 2014 – Sep 2015 |
| Department of Health and Human Services | PRECLINICAL TESTING OF AN O-GLCNACASE INHIBITOR TO BLOCK NEURODEGENERATION FOR AD | $124.7K | FY2008 | Aug 2008 – May 2010 |
| Department of Health and Human Services | GENETIC ANALYSIS OF IDIOPATHIC-TYPE CURVATURE IN MODEL TELEOSTS | $117.1K | FY2008 | Jul 2008 – Jun 2010 |
| Department of Commerce | SAWFISH CONSERVATION PLANNING IN EAST AFRICA | $115K | FY2016 | Oct 2015 – Mar 2018 |
| Department of Health and Human Services | AN UNTARGETED NMR METABOLOMICS PLATFORM FOR FUNCTIONAL ANNOTATION OF NATURAL PRODUCT EXTRACTS. | $88.6K | FY2018 | Sep 2018 – Aug 2021 |
| Department of Commerce | SECURING A FUTURE FOR SAWFISHES: AN EXPERT WORKSHOP AND AWARENESS-RAISING ACTIVITIES | $64K | FY2012 | May 2012 – Dec 2013 |
| VA/DoDDepartment of Defense | DEVELOPMENT OF PIEZOELECTRIC SINGLE CRYSTALS (PIEZOCRYSTALS) STANDARD | $39.5K | FY2026 | Mar 2026 – Feb 2030 |
| Department of Agriculture | BEHAVIORAL ECOLOGY OF HOST SELECTION BY THE ASIAN LONGHORNED BEETLE: DEVELOPMENT OF A DETECTION METHODS | $25K | FY2006 | Aug 2006 – Jul 2011 |
| Department of Commerce | LAND-USE AND SEDIMENTATION PATTERNS IN SAINT LUCIA IN RELATION TO THEIR IMPACTS ON CORAL REEFS | $18K | FY2010 | Oct 2009 – Sep 2011 |
| VA/DoDDepartment of Defense | WORKSHOP ON RELAXOR-BASED PIEZOELECTRIC SINGLE CRYSTALS | $15K | FY2011 | Mar 2011 – Dec 2011 |
| Department of Agriculture | BEHAVIORAL ECOLOGY OF HOST SELECTION BY THE ASIAN LONGHORNED BEETLE: DEVELOPMENT OF A DETECTION METHODS | $15K | FY2006 | Aug 2006 – Jul 2011 |
| VA/DoDDepartment of Defense | CSP - THE 6TH INTERNATIONAL WORKSHOP ON RELAXOR FERROELECTRICS (IWRF-2018) | $13.9K | FY2018 | Jul 2018 – Dec 2018 |
| VA/DoDDepartment of Defense | CSP - THE 13TH INTERNATIONAL SYMPOSIUM ON FERROIC DOMAINS & MICRO- TO NANO-SCOPIC STRUCTURES (ISFD-13) | $12.5K | FY2016 | Jul 2016 – Jul 2017 |
| Department of the Interior | EFFECTS OF CLIMATE CHANGE ON MONTANE AMPHIBIANS | $10.4K | FY2014 | Sep 2014 – May 2016 |
| VA/DoDDepartment of Defense | THE 20TH IMS NEW RESEARCHERS CONFERENCE | $7,446.02 | FY2018 | Aug 2018 – Sep 2018 |
| Department of State | TO COVER TRAVEL COSTS FOR SEVERAL U.S. SPEAKERS TO PARTICIPATE IN CLEAN ENERGY CONFERENCE. | $6,851 | FY2019 | Apr 2019 – Oct 2019 |
| Department of State | THE AWARD WILL BE USED TO COVER VENUE ROOM RENTAL AND PARTICIPATION OF UP TO EIGHT U.S. AUTHORS (HONORARIUM AND TRAVEL TO PARTICIPATE IN THE READING | $4,000 | FY2010 | Sep 2010 – Jun 2011 |
| Department of Agriculture | IDENTIFICATION, CHARACTERIZATION, AND VALIDATION OF GENETIC MUTATIONS INCURRED DURING IN VITRO ATTENUATION OF MAREK#18;S DISEASE VIRUS | $3,000 | FY2010 | Feb 2010 – Dec 2013 |
| Department of Health and Human Services | RELIABILITY OF MEASUREMENT TOOLS AND CHALLENGES TO ADHERENCE CLINICAL TRIALS AMON | $0 | FY2009 | Sep 2009 – Aug 2010 |
Department of Health and Human Services
$12.1M
VANCOUVER DRUG USERS STUDY: EVALUATING THE NATURAL HISTORY OF INJECTION DRUG USE
Department of Health and Human Services
$5.4M
LOCALIZED ECONOMIC MODELING TO OPTIMIZE PUBLIC HEALTH STRATEGIES FOR HIV TREATMENT AND PREVENTION
Department of Health and Human Services
$3.8M
SYNTHETIC BACTERIAL ANALOGS OF MAMMALIAN OLIGOMANNOSE FOR ELICITING NEUTRALIZING ANTIBODIES TO THE HIGH-MANNOSE PATCH ON HIV ENV
Department of Health and Human Services
$2.7M
TOBACCO COMPANIES, PUBLIC POLICY AND GLOBAL HEALTH
Department of Health and Human Services
$2.7M
VACCINES THAT REPLICATE THE NEUTRALIZATION-COMPETENT STRUCTURE OF THE GP41 MPER
Department of Health and Human Services
$2.4M
DAT-EMULATING TARGET TRIALS WITH BIG DATA TO STRENGTHEN THE EVIDENCE BASE FOR THE CLINICAL MANAGEMENT OF OPIOID USE DISORDER - ABSTRACT DAT18-06 IN 2016, FOLLOWING A DRAMATIC INCREASE IN OPIOID-RELATED OVERDOSE DEATHS, THE PROVINCE OF BRITISH COLUMBIA (BC), CANADA DECLARED A PUBLIC HEALTH EMERGENCY. BC REPORTED 1,510 ILLICIT DRUG OVERDOSE DEATHS IN 2018, A RATE OF 31.0 PER 100,000, PLACING IT 10TH AMONG US STATES, EQUAL TO RHODE ISLAND (31.0), BEHIND WEST VIRGINIA (57.8), OHIO (46.3) AND PENNSYLVANIA (44.3) BUT AHEAD OF NEW JERSEY (30.0), MICHIGAN (27.8) AND FLORIDA (25.1). WHILE THE FOUR-FOLD INCREASE IN OVERDOSE DEATHS OBSERVED SINCE 2012 IS LARGELY ATTRIBUTABLE TO THE CONTAMINATION OF FENTANYL AND OTHER SYNTHETIC OPIOIDS IN THE ILLICIT DRUG SUPPLY, MANY DECEDENTS HAD SOUGHT TREATMENT IN THE PAST AND EXPERIENCED RELAPSES. OPIOID AGONIST TREATMENT (OAT) IS AMONG THE MOST EFFECTIVE TOOLS AVAILABLE TO COMBAT THE EPIDEMIC. HOWEVER, OAT UPTAKE AND RETENTION IS SUB-OPTIMAL IN BC AND INTERNATIONALLY, COMPROMISED LARGELY BY SOCIAL AND STRUCTURAL FACTORS BUT ALSO DEVIATIONS FROM EVIDENCE-BASED STANDARDS OF CARE AND FRAGMENTED CARE, PARTICULARLY FOR THOSE WITH CONCURRENT DISORDERS. FURTHERMORE, A NUMBER OF ASPECTS OF CANADIAN AND US CLINICAL GUIDELINES FOR THE MANAGEMENT OF OPIOID USE DISORDER (OUD) ARE BASED ON LIMITED AND LOW-QUALITY EVIDENCE. EVEN BASIC EVIDENCE ON THE COMPARATIVE EFFECTIVENESS OF AVAILABLE TREATMENT OPTIONS OVERALL AND FOR KEY POPULATIONS IN THE FENTANYL ERA IS LACKING. THIS PROPOSAL AIMS TO APPLY CUTTING-EDGE METHODS FOR CAUSAL INFERENCE IN EMULATING A SERIES OF ‘TARGET TRIALS’ IN THREE IMMEDIATE AIMS: (1) TO DETERMINE THE COMPARATIVE EFFECTIVENESS OF METHADONE VERSUS BUPRENORPHINE/NALOXONE FOR DIFFERENT PATIENT SUBGROUPS PRESENTING FOR OAT; (2) TO DETERMINE THE IMPACT OF URINE DRUG SCREENING – A UBIQUITOUS AND NON-EVIDENCE- BASED ELEMENT OF OUD CARE – ON OAT RETENTION AND MORTALITY; AND (3) TO DETERMINE THE COMPLEMENTARY EFFECTS OF OAT ON UPTAKE AND ADHERENCE TO DIRECTING-ACTING ANTIVIRALS FOR PEOPLE WITH OPIOID USE DISORDER (PWOUD) WITH CONCURRENT HEPATITIS C VIRUS. THE ‘TARGET TRIAL’ FRAMEWORK CHANNELS COUNTERFACTUAL THEORY IN PROVIDING A FLEXIBLE BASIS FOR COMPARING THE EFFECTS OF TREATMENT AND CLINICAL MANAGEMENT STRATEGIES ON EITHER AN INTENT-TO-TREAT OR PER-PROTOCOL BASIS. WE HAVE IDENTIFIED A NUMBER OF ADDITIONAL QUESTIONS RELATED TO THE CLINICAL MANAGEMENT OF PWOUD WHERE GUIDELINES ARE SUPPORTED BY WEAKER EMPIRICAL EVIDENCE AND WILL ENDEAVOR TO ANSWER AS MANY OF THESE QUESTIONS AS POSSIBLE, PRIORITIZING ANALYSIS USING A COMMON FRAMEWORK FOCUSED ON METHODOLOGICAL RIGOR AND
Department of Health and Human Services
$2M
HAART OPTIMISM, DRUG USE AND RISKY SEXUAL BEHAVIOR AMONG MSM IN BRITISH COLUMBIA.
Department of Health and Human Services
$1.7M
AN ETHNO-EPIDEMIOLOGICAL STUDY TO ADVANCE HIV PREVENTION AND TREATMENT FOR PWUD
Department of Defense
$596.3K
DEVELOPMENT OF FERROELECTRIC MATERIALS WITH ENHANCED PIEZOELECTRIC AND OPTICAL PROPERTIES VIA DOMAIN ENGINEERING FOR ELECTROMECHANICAL TRANSDUCER APPL
Department of Defense
$594.2K
HIGH-PERFORMANCE PIEZO- AND FERROELECTRIC MATERIALS FOR ELECTROMECHANICAL TRANSDUCER APPLICATIONS
Department of Defense
$448.5K
DEVELOPMENT OF HIGH-PERFORMANCE PIEZO- AND FERROELECTRIC MATERIALS FOR ELECTROMECHANICAL TRANSDUCER APPLICATIONS
Department of Defense
$331.1K
CONTROL OF ENERGY MINIMIZATION IN HUMAN LOCOMOTION.
Department of Health and Human Services
$303K
FERTILITY DESIRE AND PREGNANCY IN A COHORT OF DISCORDANT UGANDAN COUPLES ON ART
Department of Health and Human Services
$300.2K
GENETICS, DYNAMICS AND FITNESS OF THE HIV-1 LATENT RESERVOIR
Department of Defense
$299.7K
DEVELOPMENT OF HIGH-PERFORMANCE PIEZO- AND FERRO-ELECTRIC MATERIALS FOR ELECTROMECHANICAL TRANSDUCTION APPLICATIONS
Department of Health and Human Services
$295.3K
EXPLORING ANTIBODY RECOGNITION OF THE V3 REGION ON HIV-1 TO GUIDE VACCINE DESIGN
Department of Health and Human Services
$291.5K
THE NON-FATAL OVERDOSE CRISIS: SEX AND GENDER DIFFERENCES IN HEALTHCARE UTILIZATION AND HEALTH OUTCOMES OF PEOPLE LIVING WITH AND WITHOUT HIV BETWEEN 2012 AND 2020 - PROJECT SUMMARY/ABSTRACT THE OVERDOSE (OD) CRISIS CONTINUES TO DEVASTATE COMMUNITIES ACROSS NORTH AMERICA. DESPITE 90% OF PARAMEDIC- ATTENDED ODS IN BRITISH COLUMBIA (BC), CANADA BEING NON-FATAL, MUCH OF THE RESEARCH HAS FOCUSED ON FATAL ODS. WHILE MEN ACCOUNT FOR OVER 70% OF FATAL ODS, THERE IS EVIDENCE OF A MORE BALANCED DISTRIBUTION OF MEN AND WOMEN EXPERIENCING NON-FATAL ODS (NFODS); FURTHER, WOMEN HAVE HIGHER MORTALITY RATES IN THE YEAR FOLLOWING AN NFOD. PEOPLE LIVING WITH HIV (PLHIV) ARE DISPROPORTIONATELY AFFECTED BY THE OD CRISIS AND ARE AT INCREASED RISK OF FATAL ODS, YET LITTLE IS KNOWN ABOUT THE LONGER-TERM IMPACTS OF NFODS ON PLHIV IN TERMS OF ADVERSE HEALTH OUTCOMES AND HEALTHCARE UTILIZATION (HCU). CONSIDERING THE INCREASINGLY HIGH RATES OF NFODS, GENDERED DIFFERENCES IN MORTALITY FOLLOWING AN NFOD, AND KNOWLEDGE GAPS CONCERNING HEALTH OUTCOMES FOLLOWING AN NFOD, THIS PROPOSAL SEEKS FUNDING TO INVESTIGATE THE ROLE OF SEX, GENDER, AND HIV STATUS IN DIFFERENTIAL NFOD OUTCOMES. BC’S UNIVERSAL HEALTHCARE SYSTEM AND DATA CENTRALIZATION ENABLED THE COMPARATIVE OUTCOMES AND SERVICE UTILIZATION TRENDS (COAST) STUDY, A POPULATION-BASED LONGITUDINAL COHORT COMPRISED OF LINKED ADMINISTRATIVE HEALTH DATASETS ON ALL KNOWN ADULT PLHIV AND A 10% RANDOM SAMPLE OF THE GENERAL POPULATION IN BC. USING COAST, WE AIM TO: (1) GENERATE ESTIMATES FOR THE INCIDENCE RATES OF FATAL AND NONFATAL ODS AMONG PEOPLE LIVING WITH AND WITHOUT HIV (2012-2020) IN BC; (2) ASSESS AND COMPARE CHANGES IN HEALTH CARE UTILIZATION, CHRONIC COMORBIDITY, AND MORTALITY AMONG PEOPLE LIVING WITH AND WITHOUT HIV WHO EXPERIENCED AN NFOD, MODIFIED BY SEX AND GENDER; AND (3) ASSESS AND COMPARE CHANGES IN HIV TREATMENT OUTCOMES IN PEOPLE LIVING WITH HIV WHO EXPERIENCED AN NFOD, MODIFIED BY SEX AND GENDER. THIS PROJECT WILL ALSO INVOLVE THE DEVELOPMENT OF A COMMUNITY ADVISORY BOARD (CAB) FOR PROPOSED AND FUTURE PROJECTS. THE CAB WILL PROVIDE GUIDANCE TO ENSURE RESEARCH SOUNDNESS AND RELEVANCE TO THE COMMUNITY THROUGHOUT THE RESEARCH AND KNOWLEDGE MOBILIZATION PROCESSES. OUR COLLABORATIVE RESEARCH WILL BE AN OPPORTUNITY TO EXPLORE OTHER RESEARCH POSSIBILITIES INITIATED BY THE CAB AS IMPORTANT FOR WOMEN AND GENDER MINORITIES LIVING WITH AND WITHOUT HIV WHO ARE AFFECTED BY THE OD CRISIS. IN RESPONSE TO THE NATIONAL INSTITUTE ON DRUG ABUSE NOTICE OF SPECIAL INTEREST NOT-DA- 21-021 TO ADVANCE RESEARCH SPECIFIC TO WOMEN AND OTHER UNDERREPRESENTED POPULATIONS INCLUDING GENDER MINORITIES, THIS PROPOSAL WILL INFORM FUTURE CAB-LED CYCLES OF INQUIRY AND ANALYSIS AMONGST OUR TEAM TO ANSWER RELEVANT RESEARCH QUESTIONS AND ADDRESS THE IDENTIFIED NEEDS OF CISGENDER WOMEN AND GENDER MINORITIES LIVING WITH AND WITHOUT HIV AFFECTED BY THE OD CRISIS.
Department of Health and Human Services
$288.3K
RELEVANCE OF SERUM MANNOSIDASE RESISTANCE TO THE SPECIFICITY OF OLIGOMANNOSE-TARGETING ANTIBODIES - PROJECT SUMMARY THE GLYCANS THAT DECORATE THE HIV ENVELOPE GLYCOPROTEIN SPIKE (ENV) ARE CATEGORIZED NOMINALLY AS ‘SELF’ ANTIGENS GIVEN THAT THEY ARE IMPARTED BY THE MAMMALIAN CELL’S GLYCOSYLATION MACHINERY. HOWEVER, GLYCANS OF THE OLIGOMANNOSE-TYPE FOUND ON GP120 ARE MOSTLY CLUSTERED INTO A PATCH, CREATING A ‘NON-SELF’ ARCHITECTURE. THIS OLIGOMANNOSE PATCH IS VULNERABLE TO RECOGNITION BY ANTI-HIV BROADLY NEUTRALIZING ANTIBODIES (BNABS). GIVEN THE POTENCY AND BREADTH OF BNABS TO THE OLIGOMANNOSE PATCH, THERE IS GREAT INTEREST IN DEVELOPING IMMUNIZATION STRATEGIES TO ELICIT SIMILAR BNABS. THIS PROJECT AIMS TO FILL A GAP IN UNDERSTANDING BARRIERS TO THE ELICITATION OF OLIGOMANNOSE-SPECIFIC BNABS. WE AND OTHERS HAVE RECENTLY REPORTED ON A SOLUBLE MANNOSIDASE FOUND IN MAMMALIAN SERUM THAT TRIMS OLIGOMANNOSIDES ON GLYCOCONJUGATES DESIGNED TO ELICIT OLIGOMANNOSE-SPECIFIC ANTIBODIES UPON IMMUNIZATION. SUCH TRIMMING WOULD EXPLAIN WHY IMMUNIZING WITH OLIGOMANNOSIDIC GLYCOCONJUGATES TYPICALLY YIELDS ANTIBODIES THAT BIND WELL TO SUBSTRUCTURES OF OLIGOMANNOSE BUT THAT BIND WITH SUBSTANTIALLY LOWER AVIDITY TO FULL-SIZED OLIGOMANNOSE AS PRESENTED ON ENV; THE LATTER TYPIFIES THE BINDING MANNER OF BNABS THAT TARGET THE OLIGOMANNOSE PATCH. IN THIS APPLICATION, WE PROPOSE TO DETERMINE THE EXTENT TO WHICH SERUM MANNOSIDASE ACTIVITY IS RELEVANT TO THE QUALITY OF OLIGOMANNOSE-SPECIFIC ANTIBODY RESPONSES. SPECIFICALLY, WE INTEND TO CONSTRUCT A MANNOSIDASE-RESISTANT GLYCOSIDE, THUS REPRESENTING THE GREATEST POSSIBLE RESISTANCE TO MANNOSIDASE TRIMMING, AND DETERMINE THE SPECIFICITY OF THE ENSUING ANTIBODY RESPONSE COMPARED TO ITS MANNOSIDASE- SENSITIVE OPPOSITE. THE PROJECT WILL TAKE ADVANTAGE OF OUR PUBLISHED WORK OF A BACTERIALLY INSPIRED MIMIC OF OLIGOMANNOSE THAT, AS A NEOGLYCOCONJUGATE, ELICITS MODEST LEVELS OF HIV-NEUTRALIZING ANTIBODIES. WE WILL INVESTIGATE ANTIBODY RESPONSES AT THE POLYCLONAL SERUM LEVEL AS WELL AS THE MONOCLONAL LEVEL; THE LATTER SHOULD REVEAL SIMILARITIES, IF ANY, BETWEEN THE ELICITED ANTIBODIES AND EXISTING BNABS. IN SUM, WE EXPECT THE RESULTS OF THIS PROJECT TO SHED LIGHT ON BARRIERS TO EVOKING ANTIBODIES WITH CAPACITY TO BIND THE HIGHLY VULNERABLE OLIGOMANNOSE PATCH ON HIV ENV. ALTHOUGH THE DIFFICULTY IN ELICITING OLIGOMANNOSE-SPECIFIC BNABS IS OFTEN ASSUMED TO STEM FROM B CELL TOLERANCE, OUR PRELIMINARY STUDIES PROVIDE EVIDENCE FOR SERUM MANNOSIDASE POSING AT LEAST AN ADDITIONAL HINDRANCE.
Department of Defense
$200K
DEVELOPMENT OF NOVEL HYBRID ORGANIC-INORGANIC HALIDE PEROVSKITE MATERIALS FOR PIEZOELECTRIC AND MULTIFUNCTIONAL DEVICES
Department of Health and Human Services
$197.2K
ORIGIN OF ANTIBODIES WITH LONG CDR-H3 LOOPS IN HIV INFECTION & AUTOIMMUNE DISEASE
Department of Agriculture
$175.3K
IDENTIFICATION CHARACTERIZATION AND VALIDATION OF GENETIC MUTATIONS INCURRED DURING IN VITRO ATTENUATION OF MAREK'S DISEASE VIRUS
Department of Defense
$158.2K
DEVELOPMENT OF HIGH-PERFORMANCE PIEZO- AND FERROELECTRIC SINGLE CRYSTALS FOR ELECTROMECHANICAL TRANSDUCER APPLICATIONS
Department of Defense
$126K
THE EFFECT OF NORMOXIC DIVES ON NARCOSIS AND HEART FUNCTION IN HUMAN AND CELLULAR MODELS
Department of Health and Human Services
$124.7K
PRECLINICAL TESTING OF AN O-GLCNACASE INHIBITOR TO BLOCK NEURODEGENERATION FOR AD
Department of Health and Human Services
$117.1K
GENETIC ANALYSIS OF IDIOPATHIC-TYPE CURVATURE IN MODEL TELEOSTS
Department of Commerce
$115K
SAWFISH CONSERVATION PLANNING IN EAST AFRICA
Department of Health and Human Services
$88.6K
AN UNTARGETED NMR METABOLOMICS PLATFORM FOR FUNCTIONAL ANNOTATION OF NATURAL PRODUCT EXTRACTS.
Department of Commerce
$64K
SECURING A FUTURE FOR SAWFISHES: AN EXPERT WORKSHOP AND AWARENESS-RAISING ACTIVITIES
Department of Defense
$39.5K
DEVELOPMENT OF PIEZOELECTRIC SINGLE CRYSTALS (PIEZOCRYSTALS) STANDARD
Department of Agriculture
$25K
BEHAVIORAL ECOLOGY OF HOST SELECTION BY THE ASIAN LONGHORNED BEETLE: DEVELOPMENT OF A DETECTION METHODS
Department of Commerce
$18K
LAND-USE AND SEDIMENTATION PATTERNS IN SAINT LUCIA IN RELATION TO THEIR IMPACTS ON CORAL REEFS
Department of Defense
$15K
WORKSHOP ON RELAXOR-BASED PIEZOELECTRIC SINGLE CRYSTALS
Department of Agriculture
$15K
BEHAVIORAL ECOLOGY OF HOST SELECTION BY THE ASIAN LONGHORNED BEETLE: DEVELOPMENT OF A DETECTION METHODS
Department of Defense
$13.9K
CSP - THE 6TH INTERNATIONAL WORKSHOP ON RELAXOR FERROELECTRICS (IWRF-2018)
Department of Defense
$12.5K
CSP - THE 13TH INTERNATIONAL SYMPOSIUM ON FERROIC DOMAINS & MICRO- TO NANO-SCOPIC STRUCTURES (ISFD-13)
Department of the Interior
$10.4K
EFFECTS OF CLIMATE CHANGE ON MONTANE AMPHIBIANS
Department of Defense
$7,446.02
THE 20TH IMS NEW RESEARCHERS CONFERENCE
Department of State
$6,851
TO COVER TRAVEL COSTS FOR SEVERAL U.S. SPEAKERS TO PARTICIPATE IN CLEAN ENERGY CONFERENCE.
Department of State
$4,000
THE AWARD WILL BE USED TO COVER VENUE ROOM RENTAL AND PARTICIPATION OF UP TO EIGHT U.S. AUTHORS (HONORARIUM AND TRAVEL TO PARTICIPATE IN THE READING
Department of Agriculture
$3,000
IDENTIFICATION, CHARACTERIZATION, AND VALIDATION OF GENETIC MUTATIONS INCURRED DURING IN VITRO ATTENUATION OF MAREK#18;S DISEASE VIRUS
Department of Health and Human Services
$0
RELIABILITY OF MEASUREMENT TOOLS AND CHALLENGES TO ADHERENCE CLINICAL TRIALS AMON
Source: Federal Audit Clearinghouse (fac.gov)
No federal single audit records found for this organization.
Single audits are required for entities expending $750,000+ in federal awards annually.
Tax Year 2024 · Source: IRS e-Filed Form 990
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: FORGN
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2023 | $656.3M | $226.1M | $647.8M | $2.1B | $927.4M |
| 2022 | $690.3M | $273.2M | $668.6M | $2.2B | $1B |
| 2021 | $659.1M | $256.3M | $626.2M | $2B | $953.5M |
| 2020 | $571.2M | $204.8M | $542.1M | $1.6B |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
Financial data: IRS Form 990 via ProPublica Nonprofit Explorer (Tax Year 2023)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2024)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File · ProPublica Nonprofit Explorer
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Joy Johnson | President Vice - Chancellor | — | $0 | $0 | $335.6K | $335.6K |
| Dugan Clive O'Neil | Vice President - Research And International | — | $0 | $0 | $230.7K | $230.7K |
| Martin Puchurko | Vice President - Finance Administration | — | $0 | $0 | $224.2K | $224.2K |
| Wade Parkhouse | Former Vice President - Academic Provost | — | $0 | $0 | $216.6K | $216.6K |
| Yabome Gilpin-Jackson | Vice President - Pei | — | $0 | $0 | $216.2K | $216.2K |
| Joanne Curry | Vice President - External Relations | — | $0 | $0 | $214.6K | $214.6K |
| Erin Lori Morantz | VP Advancement Alumni Engagement | — | $0 | $0 | $207.3K | $207.3K |
| Dilson Etchevery Rassier | Vice President - Academic Provost | — | $0 | $0 | $161.6K | $161.6K |
Joy Johnson
President Vice - Chancellor
$335.6K
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$335.6K
Dugan Clive O'Neil
Vice President - Research And International
$230.7K
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$230.7K
Martin Puchurko
Vice President - Finance Administration
$224.2K
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$224.2K
Wade Parkhouse
Former Vice President - Academic Provost
$216.6K
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$216.6K
Yabome Gilpin-Jackson
Vice President - Pei
$216.2K
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$216.2K
Joanne Curry
Vice President - External Relations
$214.6K
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$214.6K
Erin Lori Morantz
VP Advancement Alumni Engagement
$207.3K
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$207.3K
Dilson Etchevery Rassier
Vice President - Academic Provost
$161.6K
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$161.6K
Highest compensated employees who are not officers or directors.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Andrew Gemino | Assoc Dean Beedie Business School | — | $0 | $0 | $333.7K | $333.7K |
| Angela Kanana Kaida | Professor | — | $0 | $0 | $281K | $281K |
| Eugene Lucas Fiume | Dean Of Applied Sciences | — | $0 | $0 | $266.1K | $266.1K |
| Donald Joseph Estep | Professor | — | $0 | $0 | $240.1K | $240.1K |
| Caroline G Colijn | Professor | — | $0 | $0 | $235.9K | $235.9K |
Andrew Gemino
Assoc Dean Beedie Business School
$333.7K
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$333.7K
Angela Kanana Kaida
Professor
$281K
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$281K
Eugene Lucas Fiume
Dean Of Applied Sciences
$266.1K
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$266.1K
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Abhishek Parmar | Student Member | — | $0 | $0 | $0 | $0 |
| Angela George | Former Alumni Order In Council | — | $0 | $0 | $0 | $0 |
| Angie Lamarsh | Board Chair | — | $0 | $0 | $0 | $0 |
| Carol Herbert | Order In Council | — | $0 | $0 | $0 | $0 |
| Carolyn Hanna | Staff Member | — | $0 | $0 | $115.9K | $115.9K |
| Daniel Leznoff | Faculty Member |
Abhishek Parmar
Student Member
$0
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$0
Angela George
Former Alumni Order In Council
$0
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$0
Angie Lamarsh
Board Chair
$0
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$0
| $765.3M |
| 2019 | $586.5M | $215.1M | $549.2M | $1.6B | $777.6M |
| 2018 | $564.4M | $202.6M | $528.5M | $1.5B | $736M |
| 2017 | $519.3M | $177.5M | $496.5M | $1.4B | $659.6M |
| 2016 | $507M | $194M | $495.6M | $1.3B | $634M |
| 2015 | $516.8M | $215.3M | $488.9M | $1.3B | $637.8M |
| 2014 | $575.9M | $246.2M | $553.6M | $1.4B | $668M |
| 2013 | $614.8M | $270.4M | $584M | $1.4B | $676.5M |
| 2012 | $654.7M | $281.2M | $574.4M | $1.4B | $689.5M |
| 2011 | $615.8M | $281.6M | $582.2M | $1.4B | $579M |
| 2021 | 990 | Data |
| 2020 | 990 | Data |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data | PDF not yet published by IRS |
| 2016 | 990 | Data |
| 2015 | 990 | Data |
| 2014 | 990 | Data |
| 2013 | 990 | Data |
| 2012 | 990 | Data |
| 2011 | 990 | Data |
| 2010 | 990 | — |
Donald Joseph Estep
Professor
$240.1K
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$240.1K
Caroline G Colijn
Professor
$235.9K
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$235.9K
| — |
| $0 |
| $0 |
| $164.3K |
| $164.3K |
| Eric Gedajlovic | Faculty Member | — | $0 | $0 | $207.6K | $207.6K |
| Gregory Malpass | Order In Council | — | $0 | $0 | $0 | $0 |
| Kamal Basra | Alumni Order In Council | — | $0 | $0 | $0 | $0 |
| Michael Mcdonald | Order In Council | — | $0 | $0 | $0 | $0 |
| Neelam Sahota | Order In Council | — | $0 | $0 | $0 | $0 |
| Paula Martin | Deputy Board Chair | — | $0 | $0 | $0 | $0 |
| Rachel Ling | Student Member | — | $0 | $0 | $0 | $0 |
| Tamara Vrooman | Chancellor | — | $0 | $0 | $0 | $0 |
| Tracy Farrell Macrae | Order In Council | — | $0 | $0 | $0 | $0 |
Carol Herbert
Order In Council
$0
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$0
Carolyn Hanna
Staff Member
$115.9K
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$115.9K
Daniel Leznoff
Faculty Member
$164.3K
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$164.3K
Eric Gedajlovic
Faculty Member
$207.6K
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$207.6K
Gregory Malpass
Order In Council
$0
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$0
Kamal Basra
Alumni Order In Council
$0
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$0
Michael Mcdonald
Order In Council
$0
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$0
Neelam Sahota
Order In Council
$0
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$0
Paula Martin
Deputy Board Chair
$0
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$0
Rachel Ling
Student Member
$0
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$0
Tamara Vrooman
Chancellor
$0
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$0
Tracy Farrell Macrae
Order In Council
$0
Hrs/Wk
—
Compensation
$0
Related Orgs
$0
Other
$0